Xanax and Benadryl: A Clinician’s Guide to Combining Alprazolam and Diphenhydramine, the Drug Interactions, Sedation Risks, Effects on Sleep and Anxiety, and What Patients Should Know

Whether xanax and benadryl can be taken together safely, why the combination amplifies sedation and respiratory depression risk, the effects on sleep, anxiety, and cognition, the differences between occasional combined use and regular daily use, the specific risks in older adults and patients with underlying conditions, and what to do when sedative use has become more than occasional.

Clinically reviewed by Dr. Ponlawat Pitsuwan, Physician and Addiction Medicine Specialist, Phuket Island Rehab.

Combining xanax (alprazolam) and benadryl (diphenhydramine) is one of the more common drug combinations in adult populations, used by patients trying to manage anxiety with sleep difficulties. The combination is not absolutely contraindicated but it produces more-than-additive sedation, increased respiratory depression risk, and substantially amplified cognitive impairment. Both medications work through different mechanisms (xanax enhances GABA-A receptor function; benadryl blocks the histamine H1 receptor and the muscarinic acetylcholine receptor), but both produce sedation through their effects on the central nervous system, and the combined effect is significantly greater than either alone. Specific risks include impaired driving, increased fall risk in older adults, anticholinergic burden that contributes to dementia risk with chronic use, and respiratory depression at higher doses. The combination should be avoided in older adults, in patients with significant respiratory or cardiac disease, in pregnant women, and in patients with prior substance use disorders. For occasional use of low doses, the combination is generally safe but should not be habitual. Patients who have been taking both medications regularly should discuss with their prescriber whether the combination is appropriate and consider alternatives. When alprazolam and diphenhydramine use has become daily, addiction medicine assessment is appropriate and integrated treatment of any underlying anxiety, insomnia, or substance use is warranted.

Why patients ask about combining xanax and benadryl

The combination of xanax and benadryl is one of the more common drug combinations in adult populations, with millions of patients taking the two medications together at some point in their lives. Patients often combine them when they have ongoing anxiety symptoms that warrant the prescription alprazolam plus sleep difficulties that they self-treat with over-the-counter benadryl. The combination is rarely discussed explicitly with the prescriber because diphenhydramine is over-the-counter, the patient may not consider it a ‘real medication’ in the same sense as the prescription alprazolam, and the cumulative sedative burden is not always apparent from each medication considered separately.

Common patient motivations for the combination include the use of xanax during the day for anxiety with benadryl at night for sleep, the use of both medications together during particularly stressful periods, the use of benadryl to enhance the sedative effect of xanax for recreational purposes (this pattern is concerning and warrants intervention), and the use of both medications to manage anxiety in social situations where the patient does not want to take additional xanax. Each pattern carries different risks, and the clinical conversation should clarify what role each medication is playing.

The combination is not absolutely contraindicated in any patient population, but it does carry several significant practical concerns that warrant attention. Both medications cause sedation, both impair cognitive function and driving performance, both have potential for dependence with chronic use, and both have specific concerning effects in older adults. The combined use amplifies each of these concerns substantially, and patients who are using both medications regularly should be aware of the cumulative effect and should have explicit conversation with their prescriber about whether the combination is the best approach to their underlying conditions.

The benadryl portion of the combination is particularly often unnoticed in the cumulative effect analysis. Diphenhydramine is widely available without prescription, is one of the most commonly used over-the-counter medications in the United States, and is the active ingredient in numerous combination products that patients may not realise contain it. The cumulative diphenhydramine load from regular nightly use plus occasional cold medications plus sleep aids plus other combination products can be substantial, and this cumulative load is what combines with the prescription xanax to produce significant clinical effect.

How each medication works

Xanax (alprazolam) is a short-acting benzodiazepine first approved by the FDA in 1981 for the treatment of generalised anxiety disorder and panic disorder. The medication works in the body and brain by binding to the benzodiazepine site on the gamma-aminobutyric acid type A (GABA-A) receptor, where it allosterically enhances the action of GABA, the principal inhibitory neurotransmitter in the central nervous system. The enhanced GABA activity produces sedation, anxiolysis, anticonvulsant activity, and skeletal muscle relaxation. The medication has rapid onset (15 to 60 minutes orally) and short duration (half-life 11 to 12 hours, with clinically effective duration of 4 to 6 hours), which makes it useful for acute anxiety and panic but also produces inter-dose anxiety in long-term users.

Benadryl (diphenhydramine) is a first-generation antihistamine first approved in 1946 for allergic conditions and now widely used as an over-the-counter sleep aid. The medication works in the body and brain by blocking the H1 histamine receptor (which produces the antihistamine effect on allergic symptoms and the sedation through inhibition of the central wakefulness signal) and the muscarinic acetylcholine receptor (which produces the anticholinergic effects including dry mouth, blurred vision, urinary retention, and cognitive impairment). The medication has slower onset (1 to 3 hours orally) and longer effective duration than its 8-9 hour half-life suggests because of distribution into tissues.

The two medications produce sedation through different mechanisms but both ultimately depress central nervous system activity. Alprazolam enhances GABA inhibition; diphenhydramine blocks histamine wakefulness signaling. The combined effect is more than additive because both pathways converge on reduced central nervous system arousal, and the inhibition of one wakefulness pathway makes the inhibition of the other more effective. Patients who take both medications together typically experience substantially more sedation than they would predict from each medication separately.

The mechanisms also produce different secondary effects that combine in concerning ways. Alprazolam produces ataxia and coordination problems through its muscle relaxant effect; diphenhydramine produces additional ataxia through its anticholinergic effect on the cerebellum. Alprazolam produces cognitive impairment through GABA enhancement in the prefrontal cortex; diphenhydramine produces additional cognitive impairment through the substantial anticholinergic burden. The combined effects on fall risk in older adults, on driving performance, and on cognitive function are substantial.

Drug interactions and pharmacological considerations

The pharmacological interaction between alprazolam and diphenhydramine is primarily pharmacodynamic rather than pharmacokinetic. The two medications do not significantly affect each other’s metabolism through the hepatic cytochrome P450 enzymes; the interaction is at the level of their combined effects on the central nervous system. The combined sedation, respiratory depression, ataxia, and cognitive impairment are greater than the sum of the individual effects, and the clinical implications of this combined burden are what make the combination concerning.

Patients on alprazolam are typically already on a medication that affects their alertness, driving capacity, and cognitive function. Adding diphenhydramine amplifies these effects and pushes the patient further into impaired territory. The morning grogginess that benadryl produces compounds the residual cognitive effects from the previous day’s alprazolam dose, and the cumulative impairment over weeks of combined use can be substantial. Patients often do not realise the degree of their impairment because tolerance to the subjective sedation develops while the objective impairment of driving, decision-making, and processing speed persists.

The respiratory depression risk of the combination is real but typically modest at therapeutic doses. Both medications produce minimal respiratory depression on their own at standard doses, but the combined effect can be significant in vulnerable populations including patients with chronic obstructive pulmonary disease, obstructive sleep apnoea, severe heart failure, or any condition that reduces respiratory reserve. The combination should generally be avoided in these patients, and any combined use should be carefully monitored.

The combination with alcohol substantially amplifies all the concerning effects. Alcohol adds to both the GABA enhancement (alprazolam pathway) and the central nervous system depression (diphenhydramine pathway), and produces respiratory depression that can become dangerous at moderate alcohol doses combined with both medications. Patients on alprazolam and benadryl should not drink alcohol while either medication is active, and ideally not while either medication is being used regularly. The triple combination of alprazolam, diphenhydramine, and alcohol has been associated with overdose deaths in case reports.

Specific risks in older adults

Older adults face the highest risks from the combination of xanax and benadryl, and both medications are independently listed on the American Geriatrics Society Beers Criteria as medications to avoid in adults over 65. The combination compounds the individual risks substantially. The Beers Criteria list alprazolam and other benzodiazepines because of the increased risk of falls and fractures, motor vehicle crashes, cognitive impairment, and overall mortality in older adults. Diphenhydramine is listed because of its substantial anticholinergic burden, association with dementia risk in long-term use, and exacerbation of cognitive impairment.

The cumulative anticholinergic burden from diphenhydramine is one of the most concerning effects in older adults. The 2015 JAMA Internal Medicine study by Shelly Gray and colleagues followed more than 3,400 adults aged 65 and older for an average of seven years and found that cumulative use of anticholinergic medications including diphenhydramine was associated with a 54 percent increased risk of dementia in the highest-exposure group. The effect appears dose-dependent, and the cumulative burden of nightly diphenhydramine over years adds substantially to the dementia risk.

The fall risk from the combination is particularly concerning in older adults. Both medications produce ataxia, both produce orthostatic hypotension, both produce sedation that can contribute to nighttime falls when getting up to use the bathroom, and both impair the cognitive function and balance reflexes that ordinarily protect against falls. Hip fractures and other fall-related injuries are leading causes of disability and death in older adults, and the combination of alprazolam and diphenhydramine measurably increases this risk.

Cognitive function in older adults is particularly affected by the combination. The cumulative cognitive impairment from chronic alprazolam (which affects memory, processing speed, and executive function) plus chronic diphenhydramine (which produces substantial anticholinergic cognitive burden) can be substantial. The impairment is often attributed by patients and families to ageing rather than to the medications, and the slow decline can be misdiagnosed as early dementia. Discontinuation of the medications often produces measurable improvement in cognitive function within weeks to months.

The clinical recommendation in older adults is to avoid the combination entirely whenever possible. If anxiety treatment is needed, alternatives such as SSRIs, buspirone, or cognitive behavioural therapy are preferred over benzodiazepines. If insomnia treatment is needed, alternatives such as cognitive behavioural therapy for insomnia, low-dose doxepin (3 to 6 mg), trazodone, or melatonin are preferred over diphenhydramine. The taper from the combination should be slow and structured to avoid withdrawal symptoms while allowing the underlying conditions to be treated by safer alternatives.

Effects on sleep and anxiety

The combination of xanax and benadryl can produce noticeably stronger sleep effect than either medication alone, which is one of the principal reasons patients use the combination. The strong sedation can be useful for occasional difficult nights but is rarely sustainable as a long-term sleep strategy. Tolerance to the sedative effects of both medications develops within weeks of regular use, prompting some patients to escalate doses; the dose escalation increases the cumulative risk without proportionally increasing the benefit. Many patients find that after months of regular combined use, the combination no longer produces the strong sleep effect it originally did, while the cumulative risks have grown.

Sleep architecture is disrupted by the combination in ways that affect the quality of the sleep even when total sleep time appears normal. Alprazolam reduces slow-wave sleep and REM sleep, both of which are important for memory consolidation, emotional processing, and overall sleep restoration. Diphenhydramine also reduces REM sleep through its anticholinergic effects. The combined effect is sleep that may be subjectively longer or deeper but that is less restorative than natural sleep, and patients often describe morning fatigue, brain fog, and emotional flatness after nights of the combined medication use.

Anxiety management with the combination is similarly complicated. The acute anxiolysis of alprazolam is supplemented by the sedative effect of diphenhydramine, which can produce a stronger anxiolytic effect than alprazolam alone. However, the strong sedation often interferes with daytime function, and the rebound anxiety between doses of alprazolam can be made worse by the post-medication grogginess of diphenhydramine. Long-term users often find that anxiety has increased rather than decreased despite the medication burden, and that the medications have become a part of the anxiety pattern rather than a solution.

Patients with panic disorder on chronic alprazolam who add benadryl for sleep often find the combination produces a cycle of medication dependence: the alprazolam manages daytime anxiety, the benadryl is needed for sleep because of the rebound anxiety from the alprazolam, and stopping either medication produces withdrawal that drives continuation. Breaking this cycle requires careful tapering of both medications and treatment of the underlying conditions with evidence-based alternatives. The work usually takes months and benefits from specialist support.

Recreational misuse and abuse patterns

The combination of alprazolam and diphenhydramine is sometimes used recreationally to enhance the sedative or dissociative effects of either medication. Patterns include using high doses of benadryl with alprazolam to produce strong sedation and dissociation, using the combination to come down from stimulants, using the combination with alcohol or opioids to amplify effects, and using diphenhydramine to potentiate diverted alprazolam. The recreational use patterns are concerning because they substantially increase the overdose risk and because they often signal broader patterns of substance use that warrant clinical assessment.

Adolescent recreational use of diphenhydramine in the ‘Benadryl challenge’ that circulated on TikTok in 2020 was associated with several reported deaths and many hospitalisations. Adolescents who combined the diphenhydramine with prescription medications including alprazolam, or with alcohol, faced amplified risks. The pattern of high-dose recreational diphenhydramine has continued in smaller numbers since the initial viral spread of the challenge, and parents and clinicians should be aware of the risk in vulnerable adolescents.

Patients with prior substance use disorders, particularly alcohol use disorder, benzodiazepine use disorder, or stimulant use disorder, are at elevated risk of problematic use of either alprazolam or diphenhydramine alone, and the risk is compounded when the two are combined. The prescribing of alprazolam in these patients should be approached with substantial caution, and any combined use with diphenhydramine should be explicitly discussed. The use of benadryl as a self-prescribed sleep aid in patients with substance use disorders is one of the patterns that addiction medicine clinicians watch for as a marker of potential broader concern.

The diversion of prescription alprazolam combined with over-the-counter diphenhydramine is also a pattern of recreational substance use that has been described in adolescent and young adult populations. Patients who obtain alprazolam from family members or from illicit sources and combine it with diphenhydramine for stronger effect are at substantial risk of accidental overdose, particularly if alcohol or other substances are added. The pattern often signals broader polysubstance use and warrants integrated addiction medicine assessment.

When the combination is genuinely indicated

Despite the concerns about the combination, there are clinical situations where short-term combined use of alprazolam and diphenhydramine is reasonable. Acute allergic reactions in a patient on alprazolam may require benadryl treatment regardless of the medication interaction, with the alprazolam dose held or reduced for the duration of the antihistamine treatment. Acute insomnia during a particularly stressful period in a patient on alprazolam may benefit from a few nights of benadryl, with a return to non-pharmacological sleep approaches as the acute stressor resolves. Single-night use during travel for jet lag management is generally acceptable.

Procedural sedation that includes both medications under medical supervision is sometimes done for specific procedures, with appropriate monitoring of respiratory and cardiac status. The combined use in these contexts is carefully calibrated to the procedure and the patient, and the dosing is conservative because of the synergistic effect. The procedural use is fundamentally different from home use in that it occurs under monitoring and with a specific time-limited indication.

Pre-operative anxiolysis combined with H1 antihistamine for allergy concerns or for nausea prophylaxis is another context where the combination is sometimes used appropriately. The patient receiving alprazolam pre-operatively for anxiety and benadryl pre-operatively for nausea or allergic precaution is generally safe under monitored conditions, with appropriate dose adjustments for the cumulative effect.

For most patients who are using alprazolam and benadryl together at home for chronic anxiety and insomnia, however, the combination is not the optimal long-term approach. Alternative strategies that produce better outcomes with lower risk include cognitive behavioural therapy for insomnia, SSRIs for chronic anxiety, mindfulness-based interventions, and the use of medications without the anticholinergic burden of diphenhydramine. The clinical conversation should explore these alternatives when patients are in patterns of regular combined use.

Tapering and discontinuation

Patients who have been on both medications regularly may need to taper from both rather than stopping abruptly. Alprazolam taper requires medical supervision because of the seizure risk with abrupt discontinuation after sustained use; the taper typically involves dose reductions of 25 percent every two weeks for short-term users and 5 to 10 percent every two to four weeks for long-term users. Diphenhydramine taper is generally less critical because the withdrawal is milder, but a structured reduction over one to two weeks is helpful to avoid severe rebound insomnia.

Common approaches include stopping the diphenhydramine first while keeping the alprazolam stable, then once the patient has adapted to sleep without benadryl, beginning the alprazolam taper. This sequence allows one medication to be discontinued at a time, makes side effects and withdrawal symptoms easier to attribute, and provides a clearer picture of the patient’s underlying sleep and anxiety status as each medication is removed. The alternative sequence (alprazolam first, then benadryl) is sometimes used but is generally less convenient because the alprazolam taper is the more difficult one.

Treatment of underlying conditions during the taper is essential. Insomnia should be addressed with cognitive behavioural therapy for insomnia, sleep hygiene optimisation, and possibly a short-term non-anticholinergic alternative such as low-dose doxepin, trazodone, or melatonin. Anxiety should be addressed with SSRIs (starting before the alprazolam taper begins so they have time to reach effect), cognitive behavioural therapy, mindfulness-based interventions, or other evidence-based approaches. The taper is much more likely to succeed when the underlying conditions are being actively treated rather than being left unaddressed.

Patients who have developed problematic use patterns with either medication, including those who have escalated doses without prescriber guidance, used diverted medication, or combined with alcohol or other substances, may benefit from addiction medicine assessment and structured residential treatment rather than outpatient taper. The Phuket Island Rehab residential program provides this kind of integrated care, with medical supervision of the taper, treatment of underlying anxiety and insomnia, and addiction medicine support for any co-occurring substance use disorder.

When drinking has joined the picture

For readers who have been combining xanax and benadryl for months or years and who also drink in patterns that have been normalised, the situation often involves a wider pattern of substance use that has developed in response to anxiety, insomnia, or life stress. The combination of regular alprazolam, regular diphenhydramine, and regular drinking produces substantial cumulative sedative load and is one of the more concerning polysubstance patterns in adult populations. Each substance has been normalised within the patient’s daily routine, and the cumulative effect on cognition, function, and overdose risk is often substantial.

Heavy drinking combined with the alprazolam-benadryl combination produces several compounding problems. The respiratory depression of all three substances combines and substantially increases the overdose risk. The cognitive impairment is dramatic, often unrecognised by the patient. The driving impairment is severe and is one of the leading patterns in benzodiazepine-related motor vehicle fatalities. The interaction with sleep architecture compounds the sleep problems that may have driven the original benadryl use, creating a cycle that is hard to break without specific intervention.

Alcohol use disorder, the clinical term for problematic alcohol use, is defined by the DSM-5 criteria including drinking more than intended, unsuccessful efforts to cut down, craving, tolerance, withdrawal, and continued use despite consequences. Many patients combining alprazolam and diphenhydramine also meet AUD criteria. Phuket Island Rehab provides residential addiction medicine treatment for benzodiazepine dependence, sedative use disorder, alcohol use disorder, and dual diagnosis cases that include co-occurring anxiety, insomnia, depression, or other mental health conditions.

Summary

Combining xanax (alprazolam) and benadryl (diphenhydramine) produces more-than-additive sedation, increased respiratory depression risk, substantially amplified cognitive impairment, and elevated fall risk. Both medications work through different mechanisms (alprazolam enhances GABA-A receptor function; diphenhydramine blocks H1 histamine and muscarinic acetylcholine receptors), but both produce sedation through central nervous system effects, and the combined effect is significantly greater than either alone. The combination should be avoided in older adults, in patients with significant respiratory or cardiac disease, in pregnant women, and in patients with prior substance use disorders. For occasional use of low doses, the combination is generally safe but should not be habitual. Patients who have been taking both medications regularly should consider alternatives including cognitive behavioural therapy for insomnia, SSRIs for chronic anxiety, and non-anticholinergic sleep aids. The combination with alcohol substantially amplifies all risks and has been associated with overdose deaths. Tapering from the combination requires careful planning, treatment of underlying conditions, and sometimes addiction medicine support. As Dr. Ponlawat Pitsuwan summarises, “The xanax and benadryl combination is one of the patterns we see most often in adult patients with chronic anxiety and insomnia. The combination is rarely the best long-term approach for either condition, and alternatives produce better outcomes with lower risk. Patients on regular combined use deserve careful taper and proper treatment of the underlying conditions.”

Frequently asked questions

Can I take xanax and benadryl together?

The combination is not absolutely contraindicated but it produces more-than-additive sedation, increased respiratory depression risk, and substantially amplified cognitive impairment. Occasional use of low doses for specific indications is generally safe. Regular daily combined use is concerning, particularly in older adults, and warrants discussion with the prescriber about alternatives.

Will xanax and benadryl together make me sleep better?

The combination produces stronger sedation than either medication alone, which can produce subjectively deeper sleep. However, sleep architecture is disrupted by both medications, particularly the REM sleep needed for emotional processing and memory consolidation. The strong sedation often produces morning grogginess, cognitive impairment that persists into the day, and reduced sleep quality despite the appearance of deeper sleep.

Is it safe to mix xanax, benadryl, and alcohol?

No. The triple combination substantially increases the risk of profound sedation, respiratory depression, accidental injury, and overdose death. The combination has been associated with fatal overdoses in case reports. Patients on alprazolam should avoid both regular benadryl use and alcohol, and the three substances should never be combined.

What are the risks of combining xanax and benadryl in older adults?

Older adults face significantly elevated risks from the combination including falls and fractures, motor vehicle crashes, cognitive impairment that may resemble dementia, and increased mortality. Both medications are listed on the American Geriatrics Society Beers Criteria as medications to avoid in adults over 65. The combination should generally be avoided entirely in older adults, with alternatives used for both anxiety and insomnia.

How do I stop taking xanax and benadryl safely?

A structured taper under medical supervision is essential. Common approach is to stop the diphenhydramine first while keeping alprazolam stable, then begin the alprazolam taper with reductions of 5 to 25 percent every two to four weeks depending on the duration of use. Treatment of underlying anxiety and insomnia with evidence-based alternatives should be ongoing during the taper. Stopping alprazolam abruptly can produce seizures.

Are there safer alternatives to combining xanax and benadryl?

Yes. Cognitive behavioural therapy for insomnia is the gold-standard treatment for chronic insomnia. Cognitive behavioural therapy for anxiety is highly effective. SSRIs are first-line medication for chronic anxiety. Low-dose doxepin, trazodone, and orexin-receptor antagonists are alternative sleep medications with better safety profiles than diphenhydramine. Buspirone is a non-sedating anxiolytic. None of these alternatives produce the dependence and cognitive harm of the alprazolam-diphenhydramine combination.

Sources

• U.S. Food and Drug Administration (FDA). Alprazolam (Xanax) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/018276s053lbl.pdf
• U.S. Food and Drug Administration (FDA). Diphenhydramine (Benadryl) product labeling. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
• Gray SL, Anderson ML, Dublin S, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Internal Medicine. 2015;175(3):401-407. https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2091745
• American Geriatrics Society Beers Criteria Update Expert Panel. 2023 AGS Beers Criteria. https://agsjournals.onlinelibrary.wiley.com/doi/10.1111/jgs.18372
• National Institute for Health and Care Excellence (NICE). Generalised anxiety disorder and panic disorder in adults: management. https://www.nice.org.uk/guidance/cg113
• U.S. Food and Drug Administration (FDA). Boxed warning on opioid and benzodiazepine combination. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warns-about-serious-risks-and-death-when-combining-opioid-pain-or
• Substance Abuse and Mental Health Services Administration (SAMHSA). National helpline. https://www.samhsa.gov/find-help/national-helpline

xanax and benadryl, xanax, alprazolam, benadryl, diphenhydramine, may, side, take, taking, drug, diphenhydramine, cause, use, risk, sedation, treatment, health, increase, alprazolam, drug interaction, benzodiazepine, antihistamine, first-generation antihistamine, GABA-A receptor, GABA, H1 histamine receptor, muscarinic acetylcholine receptor, anticholinergic, anticholinergic burden, central nervous system, CNS depressant, sedation, anxiolysis, anxiety, anxiety disorder, generalised anxiety disorder, panic disorder, insomnia, sleep, sleep aid, REM sleep, slow-wave sleep, sleep architecture, FDA, NICE, AGS Beers Criteria, JAMA Internal Medicine, Shelly Gray, University of Washington, dementia, cognitive decline, falls, fractures, motor vehicle crashes, mortality, older adults, elderly, geriatric, pregnancy, respiratory depression, hypotension, ataxia, orthostatic hypotension, fall risk, taper, structured taper, withdrawal, withdrawal symptoms, rebound anxiety, rebound insomnia, seizures, tolerance, dependence, physical dependence, psychological dependence, drug abuse, drug misuse, recreational use, TikTok Benadryl challenge, polysubstance use, alcohol, alcohol use disorder, AUD, opioid, FDA boxed warning, DSM-5, dual diagnosis, cognitive behavioural therapy, CBT, CBT-I, SSRI, escitalopram, sertraline, doxepin, trazodone, melatonin, orexin-receptor antagonist, suvorexant, lemborexant, buspirone, mindfulness, SAMHSA, NHS 111, Phuket Island Rehab, addiction medicine, residential rehab.